MRK Merck & Company, Inc.

Healthcare · Drug Manufacturers - General

3 · Weak Momentum 9.0 · Strong At risk 14y streak

130.42

-0.38%

About the company

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Website Annual reports (10-K)

2.61%

274.19%

3.40

321.8B

105.18

1.24

113.10

52-week range

130

low 77.6 high 135

Dividend deep dive

Merck & Company, Inc. (MRK), a prominent player in the Drug Manufacturers - General industry within the Healthcare sector, currently offers a dividend yield of 2.67%. This yield sits at the lower end of its five-year historical range, which spanned from a low of 2.63% to a high of 3.65%, with an average of 3.09%. The company's dividend safety status is currently designated as 'watch', and it holds a rating score of 3.0.

Dividend history

Merck has demonstrated a commitment to returning capital to shareholders, qualifying as a CCC 'contender' with a 14-year streak of consecutive annual dividend increases. The dividend has shown consistent growth, with a 3-year compound annual growth rate (CAGR) of 5.49% and a 5-year CAGR of 6.83%. Annual dividends per share have been: $1.6794 (2014), $1.7176 (2015), $1.7557 (2016), $1.7939 (2017), $1.8321 (2018), $2.0992 (2019), $2.3282 (2020), $2.60 (2021), $2.76 (2022), $2.92 (2023), $3.08 (2024), and $3.24 (2025).

Dividend safety

Merck's dividend safety is currently flagged as 'watch'. The company's payout ratio stands at 95.77% based on reported earnings per share, indicating that most of its earnings are allocated to dividends.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

Try a sample portfolio Sign up free

AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.